Cargando…
The use of remdesivir outside of clinical trials during the COVID-19 pandemic
With a scientific background from filoviruses, paramyxoviruses, SARS-CoV, and MERS-CoV, remdesivir entered into the COVID-19 battle to become one of the favorable therapeutic candidates with potential antiviral activity in the treatment of this disease. Globally, remdesivir was accessed and investig...
Autores principales: | Halimi, Vesa, Daci, Armond, Ridova, Nevenka, Panovska-Stavridis, Irina, Stevanovic, Milena, Filipce, Venko, Dimovski, Aleksandar, Grozdanova, Aleksandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503054/ https://www.ncbi.nlm.nih.gov/pubmed/32968487 http://dx.doi.org/10.1186/s40545-020-00258-8 |
Ejemplares similares
-
Current regulatory approaches for accessing potential COVID-19 therapies
por: Halimi, Vesa, et al.
Publicado: (2020) -
Prevalence of Allelic Variants and Clonality of IGHV1-69 Expressing B-Cells in Patients with Different Severity of COVID 19 Disease
por: Panovska-Stavridis, Irina, et al.
Publicado: (2021) -
A Rare Case of Superior Ophthalmic Vein Thrombosis and Thrombocytopenia Following ChAdOx1 nCoV-19 Vaccine Against SARS-CoV-2
por: Panovska-Stavridis, Irina, et al.
Publicado: (2021) -
Gaucher disease in North Macedonia: Unexpected prevalence of the N370S GBA1 allele with attenuated disease expression
por: Ridova, Nevenka, et al.
Publicado: (2022) -
Clinical and Regulatory Concerns of Biosimilars: A Review of Literature
por: Halimi, Vesa, et al.
Publicado: (2020)